PAMR1

Across TCGA pan-cancer cohorts, PAMR1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PAMR1 data layer compared with 23 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PAMR1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PAMR1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

LUAD, UCEC, and HNSC are the cancer types where PAMR1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	III,IV	0.221	0.875	.001	38	view →
UCEC	OS	Quartile	II,III,IV	0.502	1.000	.035	8	view →
HNSC	OS	Median	IV	0.979	0.730	.010	3	view →
LSCC	OS	Median	All	0.940	0.821	.027	3	view →
GBM	OS	Median	All	0.787	0.948	.017	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PAMR1–LUAD (DFS)

Open the LUAD breakdown →